Erythrocytapheresis limits iron accumulation in chronically transfused sickle cell patients.
Cerebrovascular accidents (CVA) as a complication of sickle cell disease occur most frequently in childhood. Life-long transfusion prevents recurrent stroke, but inevitably leads to iron overload. Although effective chelation exists, many patients are not compliant. Erythrocytapheresis, an automated method of red blood cell exchange, was evaluated as an alternative to control transfusion-related iron load. Eleven patients with sickle cell anemia and a history of stroke were converted from simple transfusion to pheresis. Total time on pheresis for the group averaged 19 months (range 4-36 months). No significant complications occurred with a mean pre-pheresis hemoglobin S (Hb S) level of 44%. Blood utilization increased by an average of 50%. The effect of pheresis on serum ferritin depended on the patient's pre-pheresis ferritin level and chelation regimen. Ferritin levels remained stable for chelated patients with ferritin levels > or = 5,000 ng/ml, but decreased in a chelated patient with a pre-pheresis ferritin level of 4,000 ng/ml. For non-chelated patients with significant pre-pheresis iron load, ferritin levels remained stable. No patient on chelation prior to pheresis was able to discontinue deferoxamine. However, one patient with pre-pheresis ferritin of 500 ng/ml maintained serum ferritin levels < 200 ng/ml for 36 months of pheresis without chelation. Pheresis is more expensive than simple transfusion unless the cost of chelation and organ damage from iron overload are considered. Erythrocytapheresis is a safe method of controlling Hb S levels and limiting or preventing iron load in chronically transfused sickle cell patients.
Hilliard
L M
LM
Department of Pediatrics, University of Alabama at Birmingham, USA. lhilliard@peds.uab.edu
Williams
B F
BF
Lounsbury
A E
AE
Howard
T H
TH
D000293:Adolescent; D000328:Adult; D000755:Anemia, Sickle Cell / Q000628:therapy*; D015913:Chelation Therapy; D002648:Child; D003362:Cost-Benefit Analysis; D016238:Cytapheresis / Q000191:economics; D017707:Erythrocyte Transfusion / Q000009:adverse effects / Q000191:economics / Q000706:statistics & numerical data; D004912:Erythrocytes / Q000166:cytology*; D005260:Female; D005293:Ferritins / Q000097:blood; D006801:Humans; D019190:Iron Overload / Q000517:prevention & control* / Q000628:therapy; D008297:Male
D005293:Ferritins